Institute of HIV/AIDS Prevention, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong, China.
Institute of Pathogenic Microorganism, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, Guangdong, China.
Infect Genet Evol. 2024 Sep;123:105653. doi: 10.1016/j.meegid.2024.105653. Epub 2024 Aug 5.
In Guangdong Province, hepatitis C virus (HCV) had been found to confer resistance to direct-acting antivirals (DAAs). There were few studies of HCV subtypes and resistance-associated substitutions (RASs) of HCV in different high-risk populations. In this study, we aimed to determine the subtype distribution and the RASs in high-risk population groups, including drug users (DU), men who have sex with men (MSM), female sex workers (FSW), and male patients with sexually transmitted diseases (STD) in Guangdong Province (a highly developed province with a large population).
Using a city-based sampling strategy,1356 samples were obtained from different population groups. Phylogenetic analyses determined subtypes based on Core, NS5B, or NS5A sequences. HCV subtype distribution and RASs in various risk groups and regions were analyzed.
Ten subtypes, of which 6 h and 6 k were novel in Guangdong, were identified. The primary subtype among all risk groups was 6a. RASs in 1b and 3a were different from those observed in other studies. Subtype 3b in western Guangdong was higher than the other three regions. No RASs were found in 6a or any other genotype 6.
The HCV subtypes are expanding in high-risk populations in Guangdong. Drug use by other risk groups and commercial sex by DU may bridge the dissemination of 6a from DU to other populations. The RAS profiles of 1b and 3a differed from those reported in studies conducted in southwestern China. Further research is required to determine the reason for this discrepancy. Moreover, the combination of RASs was high in subtype 3b. To guide HCV treatment of subtype 3b, pretreatment subtyping of HCV genotype 3 should be considered in western cities in the near future.
在广东省,丙型肝炎病毒(HCV)已被发现对直接作用抗病毒药物(DAA)具有耐药性。针对不同高危人群的 HCV 亚型和耐药相关取代(RAS)的研究较少。本研究旨在确定包括吸毒者(DU)、男男性行为者(MSM)、性工作者(FSW)和男性性传播疾病(STD)患者在内的高危人群中 HCV 亚型的分布和 RAS。
采用基于城市的抽样策略,从不同人群中获得了 1356 个样本。基于核心、NS5B 或 NS5A 序列的系统进化分析确定了亚型。分析了不同风险群体和地区 HCV 亚型分布和 RAS。
鉴定出 10 种亚型,其中 6 种为广东新亚型。所有风险群体的主要亚型为 6a。1b 和 3a 的 RAS 与其他研究观察到的不同。粤西地区 3b 亚型的比例高于其他三个地区。6a 或任何其他基因型 6 均未发现 RAS。
HCV 亚型在广东高危人群中不断扩展。其他风险群体的药物使用和 DU 的商业性行为可能会使 6a 从 DU 传播到其他人群。1b 和 3a 的 RAS 特征与中国西南部研究报告的不同。需要进一步研究以确定这种差异的原因。此外,3b 亚型的 RAS 组合较高。为了指导 3b 亚型的 HCV 治疗,在不久的将来,应考虑在西部地区对 HCV 基因型 3 进行治疗前的亚型分类。